A COMPARATIVE STUDY ON EFFICACY AND SAFETY OF TOLPERISONE VERSUS TIZANIDINE IN PATIENTS SUFFERING FROM ACUTE LOW BACK PAIN WITH MUSCLE SPASM
DOI:
https://doi.org/10.22159/ajpcr.2021.v14i12.43295Keywords:
Tolperisone, Low back pain, Tizanidine, Muscle spasmAbstract
OBJECTIVES: The objectives of this study were to compare the efficacy and safety of Tolperisone tablets 50 mg three times daily versus Tizanidine 2 mg tablets thrice daily for the treatment of acute low back pain with muscle spasm.
METHODS: The comparative study was carried out in 50 patients from orthopedics Dr. Pinnamaneni Siddhartha Institute of Medical Sciences and Research Foundation, Vijayawada. Only those patients fulfilling the inclusion/exclusion criteria were enrolled into the study. Participants suffering from acute low back pain with muscle spasm were divided into two groups. The participants were followed up on Day-14 as final analysis.
RESULTS: Subjects receiving Tolperisone showed a mean value of 16.43±1.16 in the Roland Morris low back pain and disability questionnaire both groups on day 1 and was reduced to 7.82±1.15 (51.94%) on day 7 and 2.56±1.53 (84.46%) on day 14. Similarly, the patients in the tizanidine group had mean value of 15.93±1.61 on day 1, which was reduced to 6.77±1.68 (57.64%) on day 7, and 2.88±1.92 (81.95%) on day 14, as comparable to the Tolperisone group. There was no statistically significant difference between the two groups, (p>0.05) for pain at rest, pain at night, restrictions of movement, changes in stiffness, changes in numbness, and changes in tenderness. There was a statistically significant difference between the two groups, (p<0.05) for pain on movement and kinesalgia.
CONCLUSIONS: Tolperisone was found comparable in efficacy to Tizanidine in improving the clinical symptoms of changes in pain Self-assessment by the patient on different applied parameters.
Downloads
References
Soonawalla DF, Joshi N. Efficacy of thiocolchicoside in Indian patients suffering from low back pain associated with muscle spasm. J Indian Med Assoc 2008;106:331-5.
Ahdhi GS, Subramanian R, Saya GK, Yamuna TV. Prevalence of low back pain and its relation to quality of life and disability among women in rural area of Puducherry, India. Indian J Pain 2016;30:111-5.
Sartini S, Guerra L. Open experience with a new myorelaxant agent for low back pain. Adv Ther 2008;25:1010-8.
Sakai Y, Matsuyama Y, Nakamura H, Katayama Y, Imagama S, Ito Z, et al. The effect of muscle relaxant on the paraspinal muscle blood flow: A randomized controlled trial in patients with chronic low back pain. Spine 2008;33:581-–7.
Golovacheva VA, Golovacheva AA, Zinovyeva OE, Golubev VL. Tolperisone in the treatment of acute and chronic nonspecific back pain. Neurol Neuropsychiatry Psychosomatics 2020;12:137-42.
Vaughan SA, Torres K, Kaye R. RESUME-1: A phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back. Pain Manag 2021. (Epub ahead of print).
Svyrydova N. Back pain treatment: A review of the 2018 recommendations. East Eur J Neurol 2018;3:33-43.
Pratzel HG, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: Results of a prospective placebo-controlled double-blind trial. Pain 1996;67:417-25.
Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004;28:140-75.
See S, Ginzburg R. Skeletal muscle relaxants. Pharmacotherapy 2008;28:207-13.
See S, Ginzburg R. Choosing a skeletal muscle relaxant. Am Fam Physician 2008;78:365-70.
Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44 11 Suppl 9:S53-9.
Elenbaas JK. Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm 1980;37:1313-23.
Published
How to Cite
Issue
Section
Copyright (c) 2021 ABDUL FAHEEM KHAN, KHANETA PARVEEN
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
